[Results of the RALES trial: good news for patients with heart failure and ... for health administrations].
Azpitarte Almagro
J
J
Servicio de Cardiología, Hospital Universitario Virgen de las Nieves, Granada. jazpitarte@lettera.net
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D004311:Double-Blind Method; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D006333:Heart Failure / Q000188:drug therapy* / Q000191:economics / Q000401:mortality; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D010919:Placebos; D011379:Prognosis; D017257:Ramipril / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013148:Spironolactone / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D013997:Time Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D000451:Mineralocorticoid Receptor Antagonists; D010919:Placebos; D013148:Spironolactone; D017257:Ramipril